Who Is a Good Candidate for Ketamine Therapy? A Guide for Pocatello Patients

By Kyle Roth, FNP-BC, APRN, MSN, MHA | Roth Family Medicine and Mental Health | Pocatello, Idaho

Ketamine therapy has emerged as one of the most significant advances in psychiatric medicine in decades. For patients who have spent years cycling through antidepressants without adequate relief, the prospect of a treatment that can produce meaningful improvement within hours — not weeks — is genuinely life-changing.

But ketamine therapy is not for everyone. Careful patient selection is the foundation of safe, effective treatment. Understanding who is a good candidate — and who isn't — is the first step toward making an informed decision about whether this treatment is right for you.

The strongest evidence base for ketamine therapy is in treatment-resistant depression — defined as major depressive disorder that has failed to respond adequately to at least two antidepressant medications of different classes at adequate doses and durations.

Multiple randomized controlled trials have demonstrated that IV ketamine produces rapid, significant antidepressant effects in TRD patients, with response rates of 50–70% in clinical settings. The mechanism — NMDA receptor antagonism and downstream promotion of neuroplasticity via BDNF — is fundamentally different from monoamine-based antidepressants, which is why it works when SSRIs and SNRIs have failed.

Key Reference: Murrough JW, et al. (2013). Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. American Journal of Psychiatry, 170(10), 1134–1142.

Ketamine has demonstrated a uniquely rapid anti-suicidal effect that is distinct from its general antidepressant properties. For patients in acute suicidal crisis, the ability to produce meaningful reduction in suicidal ideation within hours — rather than the weeks required for conventional antidepressants — represents a potentially life-saving clinical advantage.

Key Reference: Murrough JW, et al. (2015). Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biological Psychiatry, 74(4), 250–256.

Emerging evidence supports ketamine's efficacy in PTSD, including a 2021 randomized controlled trial published in the American Journal of Psychiatry demonstrating significant PTSD symptom reduction with repeated ketamine infusions compared to midazolam control. The proposed mechanisms include disruption of fear memory reconsolidation and restoration of neuroplasticity in trauma-affected brain circuits.

Generalized anxiety disorder, social anxiety disorder, and panic disorder have shown responsiveness to ketamine in clinical practice and emerging research, though the evidence base is less mature than for depression and PTSD.

Preliminary evidence suggests ketamine may produce rapid, though often transient, reductions in OCD symptom severity. This is an active area of research.

Ketamine has shown efficacy in the depressive phase of bipolar disorder, though this requires careful clinical management given the theoretical risk of mood destabilization. Patients with bipolar disorder require thorough evaluation and typically ongoing mood stabilizer therapy.

A good candidate for ketamine therapy generally has:

1. A confirmed diagnosis of TRD, PTSD, OCD, or a related condition with documented treatment history
2. Documented failure of at least two adequate antidepressant trials (for TRD candidacy)
3. Medical stability — no active cardiovascular disease, uncontrolled hypertension, or other conditions that increase anesthetic risk
4. Psychological readiness — ability to tolerate the dissociative experience of ketamine and engage with integration work
5. A support system — someone to accompany the patient to and from sessions
6. Realistic expectations — understanding that ketamine produces a response in many but not all patients, and that maintenance may be required

• Active or recent psychosis — ketamine can exacerbate psychotic symptoms. Patients with schizophrenia, schizoaffective disorder, or active psychotic episodes are not candidates.
• Uncontrolled hypertension — ketamine raises blood pressure and heart rate transiently. Severe, uncontrolled hypertension is a contraindication.
• Active substance use disorder — particularly active alcohol use disorder or stimulant use disorder. Ketamine has abuse potential, and active addiction requires treatment before ketamine candidacy can be established.
• Pregnancy — ketamine is not safe during pregnancy.
• Known hypersensitivity to ketamine or related compounds.

• History of psychosis — prior psychotic episodes require careful risk-benefit assessment
• Poorly controlled cardiovascular disease — requires cardiology clearance
• Active manic episode — bipolar patients must be in a stable, non-manic state
• Severe personality disorder — particularly borderline personality disorder with active self-harm; requires careful clinical judgment
• History of ketamine or dissociative drug abuse — requires individualized assessment
• Elevated intracranial or intraocular pressure — ketamine raises ICP and IOP

Before any ketamine treatment is initiated, we conduct a comprehensive evaluation that includes:

Medical history review: Cardiovascular history, current medications, substance use history, prior psychiatric treatment history, and documentation of prior antidepressant trials.

Psychiatric assessment: Confirmation of diagnosis, severity assessment using validated scales (PHQ-9, PCL-5 for PTSD), and assessment of psychosis risk, suicidality, and treatment goals.

Physical examination and vital signs: Baseline blood pressure, heart rate, and weight.

Laboratory work: As clinically indicated — thyroid panel, metabolic panel, CBC.

Informed consent: A thorough discussion of the mechanism of action, expected experience, potential risks, response rates, and the importance of integration work.

Safety planning: For patients with active suicidal ideation, a safety plan is established before treatment begins.

Ketamine therapy at Roth Family Medicine is administered in a calm, monitored clinical environment. Sessions typically last 45–60 minutes for IV infusion, with a recovery period afterward.

During the session, patients may experience:

• Dissociation — a sense of detachment from the body or surroundings
• Perceptual changes — altered sense of time, visual or auditory changes
• Emotional experiences — ranging from neutral to deeply meaningful
• Physical sensations — mild dizziness, nausea (managed with pre-treatment medication)

The dissociative experience typically resolves within 30–60 minutes of infusion completion. Patients must not drive for the remainder of the day.

How many ketamine sessions will I need? The standard initial course is 6 infusions over 2–3 weeks. Response is assessed after the initial series. Maintenance infusions (monthly or as needed) are often recommended for sustained benefit.

Does insurance cover ketamine therapy? IV ketamine for depression is not currently covered by most insurance plans. Intranasal esketamine (Spravato) has FDA approval for TRD and is covered by many plans when administered in a certified healthcare setting. We discuss all options during the evaluation.

How quickly will I feel results? Many patients notice improvement within 24–72 hours of the first infusion. The full benefit of the initial series is typically assessed after all 6 infusions are complete.

Can I continue my current medications during ketamine treatment? Most antidepressants can be continued. Benzodiazepines and certain other medications may need to be adjusted. This is reviewed during your evaluation.

1. Murrough JW, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression. Am J Psychiatry. 2013;170(10):1134–1142.
2. Feder A, et al. Randomized, double-blind, placebo-controlled trial of repeated ketamine administration for chronic PTSD. Am J Psychiatry. 2021;178(2):193–202.
3. Wilkinson ST, et al. The effect of a single dose of intravenous ketamine on suicidal ideation. J Clin Psychiatry. 2018;79(2):e1–e9.
4. Daly EJ, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression. JAMA Psychiatry. 2018;75(2):139–148.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Ketamine therapy should only be administered under the supervision of a qualified medical provider following a thorough evaluation.

Kyle Roth, FNP-BC, APRN, MSN, MHA | Roth Family Medicine and Mental Health | Pocatello, Idaho | 208-904-4705 | www.rothfamilymed.com